WOONSOCKET, R.I.--(BUSINESS WIRE)--June 1, 2004--CVS Corporation (NYSE: CVS) announced today that the Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its proposed transaction to acquire approximately 1,260 Eckerd drugstores as well as Eckerd's mail order and pharmacy benefits management businesses from J.C. Penney (NYSE: JCP). CVS anticipates that the Eckerd transaction will close around the end of June 2004.
As previously reported, J.C. Penney is under agreement to sell Eckerd's remaining business to The Jean Coutu Group (PJC), Inc. (TSX: PJC.A) immediately after the closing of the CVS acquisition. The waiting period for the J.C. Penney-Coutu transaction expired on May 17, 2004, so that the Hart-Scott-Rodino waiting period has now expired for both transactions.
On April 5, 2004, CVS announced it had entered into a definitive agreement under which it will acquire approximately 1,260 Eckerd drug stores, located mainly in the southern United States, in addition to Eckerd Health Services, which includes Eckerd's mail order and pharmacy benefit management businesses. With over 40 years of dynamic growth in the retail pharmacy industry, CVS is committed to being the easiest pharmacy retailer for customers to use. With 4,191 stores in 32 states and the District of Columbia, CVS has created innovative approaches to serve the healthcare needs of all its customers through its online pharmacy, CVS.com and its pharmacy benefit management and specialty pharmacy subsidiary, PharmaCare Management Services. General information about CVS is available through the Investor Relations portion of the Company's website, at http://investor.cvs.com.